At the heart of modern biomedical innovation, human embryonic stem cells stand as a foundational pillar due to their unparalleled pluripotency—the intrinsic capacity to indefinitely self-renew and differentiate into every specialized cell type in the human body. This unique biological attribute has positioned hESCs as the definitive “gold standard” against which newer models and research techniques are benchmarked. Over the past three decades, hESCs have illuminated intricate pathways of human development, enhanced disease modeling, and fueled transformative regenerative medicine strategies, thereby catalyzing a wave of novel therapeutic possibilities that were once thought unattainable.

The NIH’s long-standing investment has been instrumental in creating a thriving ecosystem around hESC research. This ecosystem comprises extensive cell line repositories, standardized and reproducible laboratory protocols, and a vast network of specialized expertise distributed across academic and clinical institutions worldwide. Such infrastructure has not only supported a robust pipeline of preclinical studies but has now advanced numerous hESC-derived treatments into late-phase clinical trials, including Phase III studies targeting complex neurodegenerative diseases such as Parkinson’s, chronic autoimmune conditions like Type 1 diabetes, and drug-resistant epileptic disorders. These developments highlight the translational potential of hESC technology in addressing some of the most intractable medical challenges of our time.

In the context of the global scientific landscape, the United States remains a dominant force, conducting nearly half of all worldwide clinical trials involving hESC-derived therapeutics as of late 2024. This statistic attests to both the scientific vitality fostered by continued federal support and the critical role that policy stability plays in maintaining research momentum. The ISSCR’s response argues that any disruption in access to hESCs or interruptions in NIH registry processes risk derailing ongoing clinical programs, threatening both patient populations eagerly awaiting new treatments and the broader research ecosystem that underpins biomedical innovation.

Emerging technologies such as induced pluripotent stem cells (iPSCs) and computational modeling systems have undeniably expanded the scientific toolkit. However, ISSCR leadership clarifies that these methods do not render hESCs obsolete. Instead, iPSCs and other stem cell alternatives rely heavily on hESCs as a benchmark to validate pluripotency and ensure biological fidelity. Unlike adult stem cells, which exhibit restricted differentiation potential and often face challenges related to scalability and culture expansion, hESCs provide a stable, reproducible, and biologically relevant reference point that remains indispensable for rigorous scientific inquiry.

Furthermore, hESCs are pivotal in advancing human-relevant drug discovery platforms and new approach methodologies (NAMs). NAMs are cutting-edge paradigms tailored to reduce preclinical reliance on animal models while enhancing the predictive power and translational relevance of toxicity and efficacy assessments. Through their well-characterized and stable nature, hESCs serve as critical reference standards in NAM development, enabling reproducibility and comparability across diverse experimental systems. This role is particularly crucial in refining target validation, minimizing late-stage drug attrition, and accelerating the overall trajectory from bench to bedside.

ISSCR’s statement also highlights the robust ethical and regulatory framework governing hESC research, which operates under stringent NIH Guidelines and complementary oversight by prominent scientific bodies. These protocols ensure that no federal funding supports the derivation of new hESC lines or activities involving the destruction of human embryos, underscoring a commitment to responsible, ethical scientific conduct. This established framework balances scientific innovation with societal concerns, fostering public trust and facilitating continued progress in this sensitive domain.

The Society’s call for evidence-based policy decisions advocates a reconsideration of the current NIH pause on registry submissions. By emphasizing that the scientific, translational, and ethical evidence collectively endorses sustained investment in hESC research, ISSCR urges NIH leadership to reaffirm its long-standing commitment to supporting high-quality, scientifically meritorious investigations. Continuity in funding and unfettered access to these cellular resources are paramount to maintaining the forward trajectory of regenerative medicine and ensuring that promising discoveries translate into tangible clinical benefits.

Importantly, ISSCR warns that policy instability at this juncture—often referred to as a translational inflection point—could precipitate prolonged setbacks in multiple biomedical sectors. The implications extend beyond stem cell science; delays in hESC research impact neurological disorders, metabolic diseases, and general regenerative therapies, potentially stalling innovations impacting millions of patients worldwide. Moreover, the cumulative value of billions of dollars in previous federal investments stands jeopardized if the infrastructure supporting hESC research is diminished or compromised.

In summation, human embryonic stem cells constitute an irreplaceable asset within the biomedical research ecosystem. Their unique biological properties and the extensive infrastructural network devoted to their study have enabled unprecedented advances in understanding human physiology and developing cutting-edge therapies. Preservation of access to hESCs aligns with sustained scientific discovery, innovation, and ultimately, the delivery of life-saving treatments that address otherwise intractable diseases. The ISSCR’s strong advocacy underscores the stakes involved and the consequential nature of sustaining federal support in this arena.

As the scientific community awaits NIH’s policy decisions, the ISSCR’s position reverberates clearly: stem cell research, particularly involving hESCs, remains vital to medical progress and public health. Moving forward, collaborative efforts among policymakers, researchers, and ethicists are essential to uphold stringent oversight while facilitating the research continuity necessary to harness the full potential of stem cell science—transforming patient care and expanding therapeutic horizons on a global scale.

Subject of Research: Human Embryonic Stem Cell Research and Policy Implications

Article Title: ISSCR Urges NIH to Lift Pause on Human Embryonic Stem Cell Registry Submissions Amid Critical Advances in Regenerative Medicine

News Publication Date: Late 2024

Web References:
https://www.isscr.org/s/ISSCR_NIH_NOT-OD-26-031_hESC_RFI_signaturecopy.pdf
https://www.isscr.org/

Keywords: Human embryonic stem cells, pluripotency, regenerative medicine, NIH Human Embryonic Stem Cell Registry, translational research, induced pluripotent stem cells, new approach methodologies, drug discovery, clinical trials, ethical oversight, biomedical innovation, stem cell policy

Autism spectrum disorder, characterized by deficits in social communication, repetitive behaviors, and often accompanied by comorbid neuroinflammation, remains a major challenge due to its multifactorial etiology and the limited efficacy of current therapies. The interaction between the gut microbiota and brain function, often referred to as the “gut-brain axis,” has recently garnered attention for its role in modulating neurodevelopment and behavior. This study by Liu et al. represents a critical advance by examining how neural stem cell therapy can simultaneously target central nervous system inflammation and peripheral microbiota imbalance, two interrelated mechanisms implicated in ASD pathogenesis.

Central to the investigation was the use of non-gene-edited neural stem cells, bypassing the complexities and potential ethical concerns associated with genetic manipulation. These stem cells were harvested and applied in a controlled, in vivo experimental setup involving Sprague-Dawley rats induced with an ASD-like phenotype. The choice of this strain, well-known for its utility in neurobehavioral studies, provided a robust platform to explore both neurological and gastrointestinal dimensions of ASD.

The researchers meticulously documented changes in behavioral patterns following stem cell transplantation. Rats exhibited marked improvements in social interaction, a core deficit in ASD, alongside reductions in repetitive behaviors. These behavioral changes were closely associated with diminishing signs of neuroinflammation, highlighted by a significant decrease in activated microglia and pro-inflammatory cytokines within various brain regions, including the prefrontal cortex and hippocampus. Such neurobiological shifts underline the capacity of neural stem cells to create a neuroprotective milieu conducive to functional recovery.

Complementing this central effect was an unexpected but highly significant modulation of the gut microbiome. Dysbiosis, a hallmark characterized by altered microbial diversity and composition, was markedly reversed. Post-treatment analyses revealed restoration of microbial taxa known for their anti-inflammatory properties and enhanced production of short-chain fatty acids, metabolites intimately linked with gut health and systemic immune regulation. This finding solidifies the concept that neural interventions can have peripheral ramifications by reinstating homeostasis within the gut-brain axis.

Liu and colleagues employed rigorous molecular techniques, including next-generation sequencing and multiplex immunoassays, to delineate these changes at a granular level. This comprehensive approach not only confirmed the dual impact on neuroinflammation and microbiota but also shed light on potential signaling pathways, such as the modulation of the vagus nerve and systemic immune factors, that mediate this bidirectional communication.

A pivotal aspect of the study was its focus on non-gene-edited stem cells, which circumvents some of the risks linked to genetic modifications, such as oncogenic potentials and immune rejection. These cells retained their inherent neurogenic and immunomodulatory properties, proving that naturally derived stem cells could exert profound therapeutic effects without genetic alteration. This strategy enhances the translational potential of the findings, as it aligns more closely with current clinical regulatory frameworks.

The implications of these results are expansive. By demonstrating an intervention that concurrently modulates central and peripheral pathologies, this work challenges the traditional compartmentalized treatment paradigms that often address neurological or gastrointestinal symptoms in isolation. Instead, it advocates for a systemic view of ASD pathophysiology, encouraging a holistic mode of treatment that may yield synergistic outcomes.

Further reinforcing the significance of this research was the detailed phenotypic characterization of treated animals. Improvements in behavioral assays such as social novelty preference and elevated plus maze tests paralleled biochemical normalization, emphasizing the functional relevance of the molecular findings. Such correlation is crucial in emphasizing the clinical relevance and potential applicability to human ASD populations.

The study also opens exciting avenues for future research. It invites exploration of optimized dosing regimens, timing, and delivery mechanisms for neural stem cells, including potential combinatorial approaches with probiotics or dietary interventions to maximize microbiota restoration. It also sets a precedent for evaluating neural stem cells in other neurodevelopmental and neuropsychiatric disorders marked by inflammation and microbiota alterations.

Importantly, the research addresses critical questions regarding the safety profile of stem cell therapy in ASD. Longitudinal analyses reported no evidence of tumorigenesis or exacerbated immune responses, bolstering the feasibility of future clinical trials. The absence of gene editing additionally alleviates public and regulatory concerns, potentially smoothing the translational pathway.

This paradigm-shifting study exemplifies how advances in stem cell biology and microbiome science can converge to offer novel therapeutic modalities. It underscores the importance of interdisciplinary approaches and technological innovation in tackling complex disorders such as autism. Moreover, it highlights the profound influence that peripheral systems exert on brain health and function, championing a comprehensive understanding of neurodevelopmental disorders.

As the field moves forward, the work by Liu et al. serves as a beacon, demonstrating that innovative biotechnological solutions, grounded in rigorous preclinical evidence, can pave the way toward effective and safe interventions. The integration of neural stem cell therapies into the ASD treatment arsenal has the potential to fundamentally alter disease trajectories, improving the quality of life for patients and families worldwide.

In conclusion, the utilization of non-gene-edited neural stem cells presents a transformative approach to mitigating the multifaceted pathophysiology of autism spectrum disorder. By synergistically targeting neuroinflammation and microbiota dysbiosis, this therapy not only ameliorates behavioral deficits but also restores biological homeostasis on multiple levels. This research charts a promising course forward, marking a critical milestone in neuroscience and regenerative medicine with far-reaching clinical implications.

Subject of Research: Neural stem cell therapy targeting neuroinflammation and microbiota dysbiosis in an autism spectrum disorder model.

Article Title: Non-gene-edited neural stem cells reverse neuroinflammation and microbiota dysbiosis in a Sprague-Dawley rat model of autism spectrum disorder.

Article References:
Liu, Z., Wu, C., Li, X. et al. Non-gene-edited neural stem cells reverse neuroinflammation and microbiota dysbiosis in a Sprague-Dawley rat model of autism spectrum disorder. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-03841-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-03841-w

Janet Rossant, editor-in-chief of Stem Cell Reports, expressed her enthusiasm about the new appointments, emphasizing the importance of integrating diverse perspectives from a global community of stem cell scientists. The augmented board promises to uphold and elevate the journal’s role as a central platform for publishing groundbreaking research that propels the field forward. The multidisciplinary expertise encompassed by the new members enables a comprehensive evaluation of studies ranging from basic stem cell mechanisms to clinical regenerative medicine strategies, ensuring that the journal maintains its high standards for impactful science communication.

Among the newly appointed editorial board members are notable figures such as Bertie Göttgens of the Cambridge Stem Cell Institute in the United Kingdom, who is recognized for his insights into gene regulatory networks governing stem cell fate decisions. Likewise, Shimpei Gotoh from Japan’s Center for iPS Cell Research and Application adds profound clinical and translational expertise, particularly in induced pluripotent stem cell (iPSC) technologies. The inclusion of such internationally respected scientists underscores the journal’s commitment to representing the breadth of stem cell research on a global scale.

The expansion further includes distinguished researchers like Kristin Hope from Canada’s University Health Network’s Princess Margaret Cancer Centre, who focuses on cancer stem cells and their influence on tumor progression and therapy resistance. The diverse geographical representation of the new board—spanning from Australia’s Murdoch Children’s Research Institute to Harvard Medical School and institutions in China, Israel, and the United States—highlights Stem Cell Reports’ dedication to fostering a truly international dialogue in stem cell science.

Supporting these new appointments, the journal’s editorial team also features five eminent associate editors with extensive expertise in areas pivotal to the future of stem cell research. Anne Grapin-Botton, from Germany’s Max Planck Institute, brings a critical focus on pancreatic development and regeneration, particularly examining how tissue architecture influences cellular differentiation pathways. Haruhisa Inoue, based at Kyoto University in Japan, combines clinical insight with pioneering iPSC modeling to study neurodegenerative diseases, bridging the gap between stem cell research and neurologic therapies.

The editorial expertise continues with Martin Pera of The Jackson Laboratory in the USA, whose work on human pluripotent stem cells encompasses essential mechanisms of self-renewal and pluripotency, with direct implications for regenerative therapies and disease modeling. April Pyle from UCLA contributes advanced knowledge in muscle stem cells and CRISPR-based therapeutic approaches to neuromuscular disorders. Ludovic Vallier from the Berlin Institute of Health offers deep insights into liver biology and the creation of organoid models for metabolic disease research and cell-based interventions.

Stem Cell Reports operates under the auspices of the ISSCR and maintains a steadfast devotion to open access publishing, allowing unrestricted dissemination of high-caliber research. Its affiliation with Cell Press ensures that the journal benefits from a robust editorial infrastructure and visibility within the life sciences community. By integrating diverse research disciplines—ranging from molecular stem cell biology to ethical frameworks surrounding stem cell applications—the journal fosters an inclusive scientific conversation that influences policy, clinical practice, and future research directions.

The recent enhancement of the editorial board not only amplifies the journal’s scientific leadership but also strategically positions Stem Cell Reports to support and shape cutting-edge advancements in the stem cell field. The board’s collective expertise ensures thorough and thoughtful peer review, facilitating the publication of work that challenges existing paradigms and introduces innovative methodologies. As stem cell science continues to unlock new potentials in regenerative medicine and disease modeling, the journal serves as a vital forum for disseminating discoveries that bear significant translational promise.

This step forward highlights the journal’s mission to serve as the “voice of the field,” fostering a dynamic and inclusive community where emerging technologies, therapeutic strategies, and ethical dialogues intersect. By continuously adapting and expanding its editorial team, Stem Cell Reports demonstrates its dedication to maintaining relevance and leadership amid the rapidly evolving landscape of biomedical research.

Researchers and clinicians alike anticipate that the journal’s augmented editorial board will expedite the flow of transformative research findings from bench to bedside. Through rigorous scrutiny and collaborative editorial oversight, Stem Cell Reports ensures that published studies meet the highest scientific standards, providing reliable and impactful knowledge to the global community. The journal represents a beacon in the field, advocating for excellence, transparency, and innovation in stem cell research dissemination.

Additionally, the journal’s visibility on social media platforms like Twitter (@StemCellReports) expands its reach, engaging a wider audience from academic researchers to laypersons interested in regenerative medicine and stem cell therapies. This commitment to broad accessibility aligns with the ISSCR’s core mission to promote excellence and facilitate the ethical application of stem cell science to improve human health worldwide.

As the field of stem cell research transcends traditional disciplinary boundaries, Stem Cell Reports embodies an integrative approach that accommodates emerging discoveries across basic, translational, and clinical domains. The bolstered editorial board exemplifies the journal’s proactive strategy to anticipate and respond to scientific challenges and ethical considerations, ensuring that Stem Cell Reports remains at the forefront of this vibrant and impactful field of biomedical research.

Subject of Research: Stem Cell Biology and Regenerative Medicine

Article Title: Leading Stem Cell Scientists Join Expanded Editorial Board of Stem Cell Reports, Amplifying Global Expertise and Editorial Excellence

News Publication Date: Not specified in the original content

Web References:

• Stem Cell Reports Editorial Board and Team: https://www.cell.com/stem-cell-reports/editorial-board
• International Society for Stem Cell Research (ISSCR): http://www.isscr.org/
• Stem Cell Reports Twitter: https://twitter.com/stemcellreports

Image Credits: Rajan et al.

Keywords: Stem cell research, Academic publishing, Open access, Science communication, Science policy, Scientific publishing, Scientific organizations

Stem cell-based embryo models represent a groundbreaking frontier in stem cell science. These three-dimensional constructs, derived from pluripotent stem cells, meticulously replicate critical phases of early human embryonic development under controlled laboratory conditions. SCBEMs enable unprecedented insights into the molecular and cellular cascade driving human embryogenesis, a realm traditionally restricted due to ethical and technical constraints surrounding human embryo research. By offering scalable and reproducible experimental platforms, these models promise to unravel complex developmental pathways, offering invaluable data that can fuel advancements in fertility treatments, congenital disease modeling, and therapeutic innovation.

The motivation behind this focused update stems from the scientific community’s recognition that SCBEMs challenge existing conceptual and regulatory paradigms. Historically, human embryo research governance has relied on established frameworks distinguishing between natural embryos and stem cell research. However, as SCBEMs increasingly blur these boundaries by mimicking embryo-like structures, there is a pressing need for tailored guidelines to ensure that scientific progress is responsibly managed without compromising ethical imperatives.

Addressing this, the ISSCR’s revised guidelines propose significant semantic and procedural changes. Notably, the prior classification dichotomy of SCBEMs as “integrated” or “non-integrated” models has been supplanted with the more inclusive and accurate terminology of “SCBEMs.” This reframing reflects a nuanced understanding of these models’ developmental capabilities and ethical considerations, steering away from rigid categorical distinctions that may hinder oversight and public trust.

The updated framework mandates that every 3D SCBEM pursued by researchers must possess a well-defined scientific rationale, articulated endpoints, and be subjected to robust oversight mechanisms aligned with prevailing ethical standards. This ensures that investigations proceed with transparency, accountability, and alignment to objectives that justify the use of such advanced models. Importantly, the guidelines reinforce the prohibition against transplanting SCBEMs into living animal or human uterine environments, thereby maintaining a clear boundary that prevents the creation of chimeric organisms or the raising of ethical dilemmas related to potential embryonic development in vivo.

In a decisive move, the guidelines also introduce a novel recommendation curtailing the ex vivo culture of SCBEMs to stages approaching viability, effectively prohibiting ectogenesis—the artificial gestation of these models to a point where they might develop autonomously outside the womb. This measure underscores the ISSCR’s commitment to ethical responsibility, preempting debates on the moral status of advanced embryo models and safeguarding against potential misuse in reproductive technologies.

The painstakingly crafted update was led by eminent stem cell biologists Amander Clark from the University of California, Los Angeles, and Janet Rossant of the Hospital for Sick Children in Toronto. Their leadership encapsulates a global, collaborative approach that harmonizes scientific innovation with ethical oversight. By focusing exclusively on SCBEM technologies, the ISSCR has adopted a nimble, responsive methodology to guideline development—one that can be adapted to future scientific breakthroughs requiring focused regulatory attention.

ISSCR President Hideyuki Okano underscored the importance of the update, emphasizing that stem cell-based embryo models are transforming the investigative landscape of early human development. He highlighted the society’s responsibility to provide clear guidance underpinned by responsibility and international consensus, ensuring that the swift momentum of scientific discovery is matched by evolved ethical frameworks.

The guidelines continue to serve as the gold standard for scientific and ethical scrutiny in stem cell research globally, fostering transparency and public confidence. They underpin the development of regulatory infrastructures in nations where stem cell oversight remains nascent, providing a robust scientific and ethical foundation that supports both research integrity and clinical translation safety.

SCBEMs stand as a potent scientific instrument capable of demystifying early human development stages that were once shrouded in obscurity due to practical and ethical limitations. Through the lens of these models, researchers can delve into the genesis of human life with molecular precision—charting cell fate decisions, lineage specification, and morphogenetic events that orchestrate embryo formation. Such insights have profound implications, ranging from understanding developmental disorders and miscarriages to refining assisted reproductive technologies, and potentially pioneering regenerative medicine approaches that mimic natural development.

The 2025 ISSCR update embodies a proactive ethical stance, recognizing the need to evolve regulatory frameworks contemporaneously with scientific advances. This anticipatory governance model is critical in an era where bioethical challenges arise rapidly alongside technological breakthroughs. By providing clarity and firm boundaries, the guidelines aim to foster an environment where innovation thrives within responsible and socially acceptable constraints.

Looking forward, the ISSCR envisions this update as a template for future agile interventions that address evolving sectors within stem cell research. Such a scalable and collaborative strategy ensures that ethical, legal, and social implications remain integral to scientific progress, fostering sustainable and globally harmonized oversight.

With a membership exceeding 5,000 professionals across more than 80 countries, the ISSCR remains the foremost international body championing excellence in stem cell science and its translation to clinical applications. Their guidelines continue to bridge scientific discovery with societal values, ensuring that the promise of stem cell research is realized through robust ethical stewardship and regulatory clarity.

Subject of Research: Human Stem Cell-Based Embryo Models and Ethical Oversight

Article Title: ISSCR Releases 2025 Update to Stem Cell Research Guidelines Targeting Embryo Model Technologies

News Publication Date: 2024

Web References:

• ISSCR Guidelines: http://www.isscr.org/guidelines
• ISSCR Embryo Models Working Group White Paper: https://www.cell.com/stem-cell-reports/fulltext/S2213-6711(25)00118-3

Image Credits: International Society for Stem Cell Research (ISSCR)

Keywords: Stem cell research, Clinical research, Scientific organizations, Science policy, Medical ethics, Research ethics